ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.

More documents

Recommendations

Info

Acknowledgements This work was supported by a grants from the Slovak Grant Agency VEGA (No.2/0041/10), (No.2/0134/13) and Grant NFM/EEA SK0095. The authors acknowledge the physicians (Peter Švec, MD PhD., Halina Vargová, PhD.) from the Department of Pediatric Oncology of University Children’s Hospital, Bratislava, Slovakia, for submitting patient bone marrow samples and referrals. References Wood, B. Cytometry, 4th Edition New Developments. Elsevier Academic Press 2004; Methods in Cell Biology 75:559–76. Fajtova, M., et al. Leuk Lymphoma. 2013 Apr 23. [Epub ahead of print] Malcovati, L., et al. Leukemia 2005; 19:776–783. Matarraz, S., et al. Cytometry Part B. 2010; 78B:154–168. 42. EFFECTS OF NATALIZUMAB ON CD4+CD25HIGH LYMPHOCYTES Helena Mareckova 1 , Zdenka Hruskova 1 , Lucia Skacikova 1 , Eva Havrdova 2 1 Inst. Immunology and Microbiology, 1 st Medical Faculty, Charles University, Prague 2 MS Centrum Neurology Clinic, 1 st Medical Faculty, Charles University, Prague Background: Natalizumab is a humanized monoclonal antibody directed against very late activation antigen 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). Blockade of VLA-4 with natalizumab may not only interfere with autoimmune mechanisms but also with central nervous system immune surveillance. Methods: Longitudinal study (follow-up between 2 and 5 years) to determine the effect of natalizumab on the frequency of CD4+CD25high regulatory T cells (Tregs) in peripheral blood (PB) and in cerebrospinal fluid (CSF). We examined 58 patients with MS treated with Tysabri (Biogen, Idec) at baseline and during therapy. Using flow cytometry with six-color imaging (Canto, BD Biosciences) following markers were assessed: CD4, CD8, CD25, CD28, CCR5 (BD) and CXCR3 (RD) in CSF and PB. Results: There was a gradual increase in circulating CD4+CD25high lymphocytes in PB during whole follow-up and marked increase in all patients in CSF between baseline and control examination. Results from CSF analysis revealed that natalizumab blocks CD4+ more than CD8+ T cells from transmigration Conclusion: The evidence for the use of natalizumab in MS from clinical trials is strong, but knowledge on effects on different immune cell populations is limited, especially for CSF. Impairment of the inhibitory function of Tregs seems to play a role in MS disease pathogenesis. Direct effects of natalizumab on T cell function have been proposed to promote some of the effects in MS, and VLA-4 blockade has been reported to modulate the activation state of CD4+ T cells. Thus, natalizumab may positively influence frequency of Tregs. Supported by IGA MZ NT / 13108 – 4 Analytical Cytometry VII 63
50. THE PROGRESSION OF HIV INFECTION IN TERMS OF LABORATORY IMMUNOLOGY Alexandra Lochmanová 1 , Lenka Olbrechtová 2 , Jitka Kolčáková 2 , Alena Zjevíková 2 1 Institute of Public Health, Department of Immunology and Allergy, Ostrava, Czech Republic; alexandra.lochmanova@zuova.cz 2 Faculty Hospital Ostrava, Clinic of Infectious Medicine, Czech Republic The pathogenesis of HIV infection includes depletion of the total body CD4+ T-cell pool, leading to immunodeficiency. This effect is accompanied by activation of numerous elements of immune system. Immune activation appears to be driven by both homeostatic response to CD4+ T/cell depletion and an inflammatory response to HIV infection. The correlation between peripheral blood CD4+ counts and the spectrum of clinical manifestations of HIV disease is well defined and has been recognized for many years. Despite its value, the peripheral blood CD4+ count is recognized as an imperfect marker of HIV disease progression. In some cases, the CD4+ percentage is a better marker of immune competence than CD4+ count. Measurements of T-cell function seems to be more effective and central to understanding HIV disease. Three types of assays are typically used to measure T-cell function: cytotoxicity, proliferation and cytokine secretion. Nonproliferation-base assessments of immune activation include measuring expression of so-called “early” cell surface markers such as HLA-DR, CD38, CD69 or CD25. A proliferative state as a definitive indicator of activation accompanied by DNA synthesis can be assessed by 3 H-thymidine uptake, measurements of intracellular proteins such as Ki67 or staining with tracking dyes (CFSE). Chronic HIV infection is accompanied by permanent activation of immune system a persistent inflammation. The intensity of this process is associated with serious outcome and poor prognosis. One of the most effective cytokine in thi sproces is IL-2, which is a potent inducer of T-cell proliferation and participates in both induction and suppression of inflammatory process. Routine laboratory monitoring of HIV patients involves determining peripheral blood CD3+, CD3+ CD4+ and CD3+CD8+ absolute count and T-cell proliferation measured by 3 H-thymidine incorporation after stimulation with PHA. It was show that the degree of cell activation, resp. functional activity, clearly reflects the depth of immunodeficiency. Reduction of functional activity indicates impairment of immune competence, whose improvement can be achieved therapeutically. Longterm unresponsiveness suggests a definite loss of immune competence and appears in the terminal stage of the disease. Impaired ability of lymphocyte proliferation may be caused by a lack of synthesis of ribonucleotides due to defect of relevant metabolic pathways. However, IL-2 seems to be one of the most important components of this process because IL2 is essential for lymphocyte proliferation. In accordance with these findings correspond clinical studies which indicate that administration of recombinant IL2 leads to a permanent increase in the number and function of CD4 + T cells in patients in both early-and late-stage of HIV infection. 64 Analytical Cytometry VII
Page 1 and 2: ABSTRACTS - ORAL PRESENTATIONS 14.
Page 3 and 4: and (iii) siRNA-mediated knockdown
Page 5 and 6: 25. PROFILING OF CHILDHOOD ACUTE LE
Page 7 and 8: more dominantly than Th1 and CD4 ce
Page 9 and 10: 29. INFLUENCE OF THE LEVEL OF CD133
Page 11 and 12: 36. B-CELL IMMUNOPHENOTYPING OF LAR
Page 13 and 14: possible mechanism behind risk alle
Page 15 and 16: isotype controls and FMO for CD14 a
Page 17: NEP developmental stages were disti
Page 21 and 22: 52. PRŮKAZ REGULAČNÍCH T LYMFOCY
Page 23 and 24: values when analysing paediatric ly
Page 25 and 26: 42,0) vs. 1,5 (0,0-28), p
Page 27 and 28: for application of proton therapy,
Page 29 and 30: effects will be also characterized
Page 31 and 32: Although multiple signalling pathwa
Page 33 and 34: an ability to recreate the tumour f
Page 35 and 36: incubated with non-filtered superna
Page 37 and 38: approaches how to detect and isolat
Page 39 and 40: progress in development of automate
Page 41 and 42: tissues is characteristic for a num
Page 43 and 44: kappaB. Beside that, we found OANO
Page 45 and 46: therapy in patients (Calderwood et
Page 47 and 48: difference in the effect caused eit
Page 49 and 50: 4 CIC bioGUNE Technology Park of Bi
Page 51 and 52: P8. PROADIFEN (SKF-525A) ATTENUATES
Page 53 and 54: models. As manifested by compromise
Page 55 and 56: P11. NEW BIOACTIVE AND FLUORESCENT
Page 57 and 58: Acetylation of histones, along with
Page 59 and 60: stimulated cells. The physiological
Page 61 and 62: h induced very minor manifestations
Page 63 and 64: chemotherapeutic drug LA-12. These
Page 65 and 66: aberrant expression, localization a
Page 67 and 68: P21. ASSESSMENT OF MITOCHONDRIAL FU
Page 69 and 70:
P23. PTEROSTILBENE: COMPARISON OF A
Page 71 and 72:
Fam123b. Amer1 has been shown very
Page 73 and 74:
In summary, we described different
Page 75 and 76:
this process. Combined treatment wi
Page 77 and 78:
Homolog 1) gene; previously identif
Page 79 and 80:
egulate expression of different gen
Page 81 and 82:
was harmful neither alone nor in co
Page 83 and 84:
P34. PHARMACOLOGICAL INHIBITION OF
Page 85 and 86:
novel chemotherapeutics with specif
Page 87 and 88:
P38. EVIDENCE OF ABNORMAL PERIPHERA
Page 89 and 90:
acid to 5-lipoxygenase. Similarly t
Page 91 and 92:
P41. WHY CAN WE SEE DIFFERENT RADIO
Page 93 and 94:
P42. ELUCIDATION OF CROSSTALK BETWE
Page 95 and 96:
P44. INSTRUMENT SETTINGS FOR EUROFL
Page 97 and 98:
e used to cultivate endothelial cel
Page 99 and 100:
concentrations 0.15, 0.2, 0.3 and 0
Page 101 and 102:
P49. NEW ANALOGS OF RHODAMINE Jiři
Page 103 and 104:
P51. FLUORESCENCE-LABELED FERROMAGN
Page 105 and 106:
could be achieved via the activatio
Page 107 and 108:
28. Pp. 1565-1570. 2008. Dearden C:
Page 109 and 110:
cells (SFC) using IFN-γ Elispot in
Page 111 and 112:
FACSCantoII flow cytometer (Becton
Page 113 and 114:
P59. EARLY DIAGNOSTICS OF CARTILAGE
Page 115 and 116:
cross-reacting group (CREG) and sha
Page 117 and 118:
the frequency of autoimmune disease
Page 119 and 120:
non-covalent bonds. For a solution
Page 121 and 122:
P65. OVULATION STIMULATION PROTOCOL
Page 123 and 124:
Acknowledgements This work was supp
Page 125 and 126:
P68. SUBPOPULATIONS OF B LYMPHOCYTE
Page 127 and 128:
triggers a process of normal blood
Page 129 and 130:
3 Department of Internal Medicine -
Page 131 and 132:
P73. THE V-ATPASE-INHIBITOR BAFILOM
Page 133 and 134:
P75. 5-FLUOROURACIL-SELECTED TUMOUR
Page 135 and 136:
We conclude that decrease in the po
Page 137 and 138:
Acknowledgements This work was supp
Page 139 and 140:
P79. NEW TYPE OF PHOTOSENSITIZER IS
Page 141 and 142:
LD11015, from GAČR 13-29358S, and
Page 143 and 144:
P83. DIFFERENTIATION OF NEURAL CRES
Page 145 and 146:
given cell type are missing and the
Page 147 and 148:
and HistoPARK (CZ.1.07/2.3.00/20.01
Page 149 and 150:
Our results show that both p38α +/
Page 151 and 152:
P90. TOLL-LIKE RECEPTOR 2 TRACKS TH
Page 153 and 154:
for chemokines in attracting “inf
Page 155:
in immune organs (Bursa of Fabricii
show all

ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.

Create successful ePaper yourself

Delete template?

Save as template?

ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.